Literature DB >> 2645949

Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia.

A LeMaistre1, M S Lee, M Talpaz, H M Kantarjian, E J Freireich, A B Deisseroth, J M Trujillo, S A Stass.   

Abstract

DNA from bone marrow and peripheral blood samples of 44 chronic myelogenous leukemia (CML) patients were analyzed for the presence of mutations of codons 12, 13 or 61 of the N-ras, H-ras, or K-ras genes. In seven patients, samples were available from both their chronic phase and blast crisis. A total of 29 samples examined were at chronic phase and 22 were at blast crisis (eight lymphoid, eight myeloid, and six undifferentiated). No mutations were identified in N-ras or H-ras. Two patients in myeloid blast crisis had K-ras mutations, one patient at codon 12, the other at codon 13. In the former patient the mutation was not present and the latter patient was not tested in chronic phase. Our findings indicate ras mutations are an infrequent late stage event in CML that occur in myeloid blast crisis.

Entities:  

Mesh:

Year:  1989        PMID: 2645949

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

Review 2.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

3.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

4.  The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.

Authors:  N Takeda; M Shibuya; Y Maru
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.